Observational Study of Bosulif for Chronic Myeloid Leukemia
This study is looking at how Bosulif, a medication for chronic myeloid leukemia (CML), works in real-world clinical practice. Researchers want to understand its safety by tracking any side effects you might experience. You could join if you are an adult (age 20 or older) with CML and are currently being treated with Bosulif, or will start treatment soon, according to your doctor's usual practice. You must have started Bosulif within the last year to be eligible. The study aims to enroll about 600 people to learn more about Bosulif's effects.
- Study design
- This is an observational study, meaning researchers will watch how Bosulif is used in regular care, not assign treatments. It plans to include about 600 adult participants with chronic myeloid leukemia.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your side effects will be monitored from when you complete Bosulif treatment until a specific period between December 2022 and December 2028.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of AEsFrom the date of bosulif treatment completion until index period (Between 30 Dec 2022 and 29 Dec 2028)